Eli Lilly and Company (LLY)
Is Eli Lilly Stock a Buy?
Like many pharma stocks, Eli Lilly (LLY -4.58%) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their medicines and will continue to order them through good times and more difficult times as well.
Why Eli Lilly Stock Flopped Today
Eli Lilly (LLY -4.58%) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of their value during the big market sell-off that day, and it wasn't only because of the general gloom.
Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - Head of IR Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger All right. So, I think we should get started here.
LLY/INCY Olumiant Shows Superior Efficacy in Pediatric Alopecia Study
Eli Lilly and INCY announce positive efficacy data from the late-stage alopecia study of baricitinib in adolescent patients.
2 Stocks That Could Split Very Soon
Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a split.
Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says
Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday at the Leerink Partners Global Healthcare Conference.
Big Money Returning for Eli Lilly
Obesity drugs, durable revenue bringing Big Money investors to Eli Lilly and Company (LLY).
US judge denies injunction to stop bar on copies of Lilly weight loss drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S.
Eli Lilly Pours $27B Into U.S. Growth—What It Means for Investors
Whatever you think of Donald Trump's tariff policies, one fact stands out: companies are looking to invest more in the United States. They want to avoid the negative impacts of tariffs on their business.
Eli Lilly and Company (LLY) TD Cowen 45th Annual Health Care Conference (Transcript)
Eli Lilly and Company (NYSE:LLY ) TD Cowen 45th Annual Health Care Conference March 4, 2025 1:50 PM ET Company Participants Jake Van Naarden - President of Lilly Oncology Conference Call Participants Stephen Scala - TD Cowen Stephen Scala Good afternoon, and welcome once again to TD Cowan's 45 Annual Health Care Conference. We're delighted to have with us, again this year, Eli Lilly.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Lilly's Jaypirca Gets CHMP Nod for 2nd Leukemia Indication in Europe
The CHMP gives a positive opinion to Eli Lilly's Jaypirca in patients with relapsed or refractory CLL in a post-BTK inhibitor setting.
